drugset / Trial / NCT03234309
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
Phase 2
Withdrawn
OHSU Knight Cancer Institute
AMAG Pharmaceuticals, Inc. · collabOregon Health and Science University · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This phase II trial studies ferumoxytol in the magnetic resonance imaging of pediatric patients with brain tumors. Magnetic resonance imaging using ferumoxytol may help in viewing a brain tumor and blood vessels in and around the tumor in a different way than the standard gadolinium-based contrast agent. Imaging with this experimental contrast agent may give doctors more information about tumor blood supply and the extent of the tumor itself.
Timeline
- Start
- 2017-10-20
- Primary completion
- 2021-08-30
- Completion
- 2021-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferumoxytol | Diagnostic / imaging agent | — | Intravenous |